©2024 Stanford Medicine
Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C
Not Recruiting
Trial ID: NCT00322179
Purpose
The response rate to interferon-based anti-viral therapy for chronic hepatitis C is lower in
patients who are obese. However, it is not clear whether this is related to suboptimal dosing
of the medication or alterated response in obese patients. Alterated immune response had been
reported in obese patients. The goal of current study is to determine the immune response to
interferon in obese compared to non-obese chronic hepatitis C in an tissue culture system.
Official Title
Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- obese (weight > 85kg and BMI>30) or non-obese patients (<75kg and BMI <25) with
chronic Hepatitis C
- Chronic Hepatitis C infection with documented HCV RNA
- Body habitat either as obese or non-obese as defined above
- Currently not under IFN therapy
- Non-African American
Exclusion Criteria:
- Body habitat neither obese or non-obese as defined for the purpose of this study
- Unable to give consent
- On immunomodulatory agents such as prednisone
- Active infection other than Hepatitis C
- Co-infection with HBV or HIV
- Active or excessive alcohol use
- Other cause of chronic Hepatitis
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305